HLA-DRB1 and myeloid sarcoma: Additionally, DMDs that lack PML risk, such as first line injectables, may be recommended for DRB1*04 carriers with MS because DRB1*04:05-positive MS patients, especially Japanese patients, have a relatively mild disease course [27, 29].